Roche preps filings for new Ocrevus injection

A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according

Roche Q3 results show steep fall-off in COVID product sales

Roche's third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products to diagnose, treat or prevent COVID-19 since the start of the p

NICE says yes to Novartis' multiple sclerosis therapy Kesimp...

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator. 

Roche hits back at Novartis with new data for MS drug Ocrevu...

Roche has hit back at Novartis’ newly-approved multiple sclerosis drug Kesimpta, with new data from its already-marketed blockbuster Ocrevus.

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

Roche raises 2019 outlook, shrugging off biosimilar threat